Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688156 | 1.00 | P2RY12 (0.48) | P2RY12ADORA3AHCY | |
| SCHEMBL16107326 | 1.00 | P2RY12 (0.48) | P2RY12ADORA3AHCY | |
| SCHEMBL1838603 | 0.94 | P2RY12 (0.49) | P2RY12ADORA3AHCY | |
| SCHEMBL29688154 | 0.94 | P2RY12 (0.49) | P2RY12ADORA3AHCY | |
| SCHEMBL1835723 | 0.89 | P2RY12 (0.48) | P2RY12ADORA3 | |
| SCHEMBL29687768 | 0.89 | P2RY12 (0.48) | P2RY12ADORA3 | |
| SCHEMBL6619320 | 0.87 | P2RY12 (0.39) | P2RY12ADORA3 | |
| SCHEMBL1831150 | 0.83 | P2RY12 (0.49) | P2RY12ADORA3 | |
| SCHEMBL14890553 | 0.83 | P2RY12 (0.49) | P2RY12ADORA3 | |
| SCHEMBL17679487 | 0.83 | P2RY12 (0.43) | P2RY12ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46276-E1 | Triazolo(4,5-D)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2017-01-17 | — | — | US | claimed |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA UK LIMITED (GB) | 2015-06-04 | — | — | US | claimed |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | ASTRAZENECA UK LIMITED (GB) | 2014-10-02 | — | — | US | claimed |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA AB (GB) | 2013-05-02 | — | — | US | claimed |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA (GB) | 2013-03-21 | — | — | US | claimed |
| US-20120165348-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | claimed |
| EP-2322513-A2 | Intermediates | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | claimed |
| EP-1135391-B1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | claimed |
| US-6525060-B1 | P2T (P2YADP or P2TAC) receptor antagonists; anticoagulant, antithrombotic | ASTRAZENECA UK LIMITED (GB) | 2003-02-25 | — | — | US | claimed |
| US-11354990-B2 | Treatment of kidney diseases associated with elevated AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-07 | — | — | US | disclosed |
| US-20200234552-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-07-23 | — | — | US | disclosed |
| US-10614684-B2 | Treatment of kidney diseases associated with elevated AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20180214450-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165348-A1 | Novel compounds | P2RX5, P2RX4, P2RY4 | P2RY12 25/4885ADORA3 35/4885AHCY 2792/4885 |
| US-10614684-B2 | Treatment of kidney diseases associated with elevated AVP | AVPR2, PKD1, AVPR1A | P2RY12 321/4885ADORA3 85/4885AHCY 271/4885 |
| US-20180214450-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | AVPR2, PKD1, AVPR1A | P2RY12 321/4885ADORA3 85/4885AHCY 271/4885 |
| US-11354990-B2 | Treatment of kidney diseases associated with elevated AVP | AVPR2, PKD1, AVPR1A | P2RY12 321/4885ADORA3 85/4885AHCY 271/4885 |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | P2RY12 12/4885ADORA3 154/4885AHCY 3453/4885 |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | THPO, PF4, P2RY4 | P2RY12 12/4885ADORA3 154/4885AHCY 3453/4885 |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | GP6, THPO, P2RY6 | P2RY12 11/4885ADORA3 159/4885AHCY 3300/4885 |
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | P2RY12 72/4885ADORA3 230/4885AHCY 2881/4885 |
| US-20200234552-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | AVPR2, PKD1, AVPR1A | P2RY12 321/4885ADORA3 85/4885AHCY 271/4885 |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | P2RY12 12/4885ADORA3 154/4885AHCY 3453/4885 |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | P2RY12 12/4885ADORA3 154/4885AHCY 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.